Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 7, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- May 8, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Mar 30, 2026Annual report · 10-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year253
SEC filings on record3906 flagged findings
Reported transactions (Form 4)33since Dec 31, 2022 · and 8 other holdings
Corporate events (8-K)30since Jan 25, 2023
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Reverse splits in 5 years
2 reverse splits in 5 years (1:15 on Sep 23, 2022, 1:75 on Apr 26, 2024) · 1:1125 cumulative
The other times: of 247 securities that repeated a reverse split in 5 years, a year later the median was worth 0.10× the price on the day of the split; 189 lost more than half and 21 rose (243 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 390)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Aug 7, 2610-Q ↗Quarterly report
- May 8, 2610-Q ↗Quarterly report
- Mar 30, 2610-K ↗Annual report
- Feb 23, 268-K ↗Current report · Entered a material agreement
- Feb 17, 26SCHEDULE 13G/A ↗Passive stake · Ikarian Capital, LLC · 4.1% · event on Dec 31, 25 · amendment
- Jan 6, 26Form 4 ↗Insider transaction
- Jan 6, 26SCHEDULE 13D/A ↗Stake with intent to influence · Fortress Biotech, Inc. · 13.4% · event on Jan 2, 26 · amendment
- Dec 31, 258-K ↗Current report · Shareholder vote results
- Dec 15, 25POS AM ↗Securities offering
- Dec 5, 25DEF 14A ↗Shareholder meeting and votes
- Nov 18, 258-K ↗Current report · Board nominations · Other events
- Nov 13, 2510-Q ↗Quarterly report
- Nov 12, 258-K ↗Current report · Entered a material agreement
- Aug 14, 2510-Q ↗Quarterly report
- Jul 18, 2525-NSE ↗Delisting or deregistration
- May 15, 2510-Q ↗Quarterly report
- Apr 30, 258-K ↗Current report · Entered a material agreement
- Apr 2, 25Form 4 ↗Insider transaction
- Apr 2, 25SCHEDULE 13D/A ↗Stake with intent to influence · Fortress Biotech, Inc. · 10.3% · event on Mar 31, 25 · amendment
- Mar 31, 2510-K ↗Annual report
- Mar 17, 258-K ↗Current report · Listing notice (8-K 3.01)
- Mar 7, 258-K ↗Current report · Other events
- Feb 14, 25SCHEDULE 13G/A ↗Passive stake · Armistice Capital, LLC · 5.0% · event on Dec 31, 24 · amendment
- Feb 14, 25SCHEDULE 13G ↗Passive stake · Ikarian Capital, LLC · 6.8% · event on Dec 31, 24
- Jan 3, 25Form 3 ↗Insider transaction
390 filings on record, the oldest from Jan 27, 16.
Listing the 25 most recent filings of the 390 on record.
152522
3 material agreements entered2025 – 2026show all 3hide
- Feb 23, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Nov 12, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Apr 30, 25Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Mar 17, 25Listing notice (8-K 3.01)8-K 3.01 ↗
- Nov 29, 24Listing notice (8-K 3.01)8-K 3.01 ↗
- Sep 27, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 26, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 13, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- May 1, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Mar 29, 24Listing notice (8-K 3.01)8-K 3.01 ↗
- Jan 8, 24Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Nov 24, 23Listing notice (8-K 3.01)8-K 3.01 ↗
- Nov 2, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Sep 28, 23Listing notice (8-K 3.01)8-K 3.01 ↗
8 older filings not shown · The record reaches back to Jun 2, 17.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- May 22, 23Listing notice (8-K 3.01)8-K 3.01 ↗
- Sep 30, 22Listing notice (8-K 3.01)8-K 3.01 ↗
- Aug 12, 22Listing notice (8-K 3.01)8-K 3.01 ↗
- May 25, 22Listing notice (8-K 3.01)8-K 3.01 ↗
- May 16, 22Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
The full record holds 15 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Fortress Biotech, Inc.13.4%Jan 2, 26SCHEDULE 13D/A ↗2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Armistice Capital, LLC5.0%Dec 31, 24SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Ikarian Capital, LLC4.1%Dec 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Dec 2, 24Sell$46Neil Herskowitz↗
- Nov 5, 24Sell$137JAY D KRANZLER↗
- Sep 30, 24Buy$1KJAY D KRANZLER↗
- Sep 27, 24Buy$7JAY D KRANZLER↗
- Dec 11, 23Sell$37KRobert L Davidow↗
- Dec 11, 23Sell$3KRobert L Davidow↗
- Dec 11, 23Sell$9KRobert L Davidow↗
- Dec 11, 23Sell$18KRobert L Davidow↗
- Dec 11, 23Sell$18KRobert L Davidow↗
- Dec 11, 23Sell$3KRobert L Davidow↗
- Sep 8, 23Buy$301KFortress Biotech, Inc.↗
- Sep 8, 23Buy$251KLINDSAY A ROSENWALD MD↗
Stock compensation, tax and giftsshow the 9 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jan 2, 26Compensationamount n/aFortress Biotech, Inc.↗
- Mar 31, 25Compensationamount n/aFortress Biotech, Inc.↗
- Sep 23, 24Compensationamount n/aDavid JinInterim PFO and COO↗
- Sep 23, 24Compensationamount n/aAlexandra MacLeanChief Executive Officer↗
- Apr 16, 24Compensationamount n/aFortress Biotech, Inc.↗
- Jan 2, 24Compensationamount n/aFortress Biotech, Inc.↗
- Mar 31, 23Compensationamount n/aFortress Biotech, Inc.↗
- Jan 3, 23Compensationamount n/aFortress Biotech, Inc.↗
- Dec 31, 22Compensationamount n/aFortress Biotech, Inc.↗
The full record holds 21 transactions and goes back to Dec 31, 22.
Its sector and its market
Avenue Therapeutics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Avenue Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Avenue Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 390 documents on file, from Jan 27, 2016 to Aug 7, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.